Functional annotation of rare gene aberration drivers of pancreatic cancer

Yiu Huen Tsang, Turgut Dogruluk, Philip M. Tedeschi, Joanna Wardwell-Ozgo, Hengyu Lu, Maribel Espitia, Nikitha Nair, Rosalba Minelli, Zechen Chong, Fengju Chen, Qing Edward Chang, Jennifer B. Dennison, Armel Dogruluk, Min Li, Haoqiang Ying, Joseph R. Bertino, Marie Claude Gingras, Michael Ittmann, John Kerrigan, Ken ChenChad J. Creighton, Karina Eterovic, Gordon Mills, Kenneth L. Scott

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

As we enter the era of precision medicine, characterization of cancer genomes will directly influence therapeutic decisions in the clinic. Here we describe a platform enabling functionalization of rare gene mutations through their high-throughput construction, molecular barcoding and delivery to cancer models for in vivo tumour driver screens. We apply these technologies to identify oncogenic drivers of pancreatic ductal adenocarcinoma (PDAC). This approach reveals oncogenic activity for rare gene aberrations in genes including NAD Kinase (NADK), which regulates NADP(H) homeostasis and cellular redox state. We further validate mutant NADK, whose expression provides gain-of-function enzymatic activity leading to a reduction in cellular reactive oxygen species and tumorigenesis, and show that depletion of wild-type NADK in PDAC cell lines attenuates cancer cell growth in vitro and in vivo. These data indicate that annotating rare aberrations can reveal important cancer signalling pathways representing additional therapeutic targets.

Original languageEnglish (US)
Article number10500
JournalNature Communications
Volume7
DOIs
StatePublished - Jan 25 2016
Externally publishedYes

Fingerprint

annotations
Molecular Sequence Annotation
Aberrations
Pancreatic Neoplasms
genes
aberration
Genes
cancer
Neoplasms
homeostasis
Adenocarcinoma
genome
Cell growth
mutations
NADP
Precision Medicine
medicine
cultured cells
Medicine
Tumors

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Tsang, Y. H., Dogruluk, T., Tedeschi, P. M., Wardwell-Ozgo, J., Lu, H., Espitia, M., ... Scott, K. L. (2016). Functional annotation of rare gene aberration drivers of pancreatic cancer. Nature Communications, 7, [10500]. https://doi.org/10.1038/ncomms10500

Functional annotation of rare gene aberration drivers of pancreatic cancer. / Tsang, Yiu Huen; Dogruluk, Turgut; Tedeschi, Philip M.; Wardwell-Ozgo, Joanna; Lu, Hengyu; Espitia, Maribel; Nair, Nikitha; Minelli, Rosalba; Chong, Zechen; Chen, Fengju; Chang, Qing Edward; Dennison, Jennifer B.; Dogruluk, Armel; Li, Min; Ying, Haoqiang; Bertino, Joseph R.; Gingras, Marie Claude; Ittmann, Michael; Kerrigan, John; Chen, Ken; Creighton, Chad J.; Eterovic, Karina; Mills, Gordon; Scott, Kenneth L.

In: Nature Communications, Vol. 7, 10500, 25.01.2016.

Research output: Contribution to journalArticle

Tsang, YH, Dogruluk, T, Tedeschi, PM, Wardwell-Ozgo, J, Lu, H, Espitia, M, Nair, N, Minelli, R, Chong, Z, Chen, F, Chang, QE, Dennison, JB, Dogruluk, A, Li, M, Ying, H, Bertino, JR, Gingras, MC, Ittmann, M, Kerrigan, J, Chen, K, Creighton, CJ, Eterovic, K, Mills, G & Scott, KL 2016, 'Functional annotation of rare gene aberration drivers of pancreatic cancer', Nature Communications, vol. 7, 10500. https://doi.org/10.1038/ncomms10500
Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M et al. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nature Communications. 2016 Jan 25;7. 10500. https://doi.org/10.1038/ncomms10500
Tsang, Yiu Huen ; Dogruluk, Turgut ; Tedeschi, Philip M. ; Wardwell-Ozgo, Joanna ; Lu, Hengyu ; Espitia, Maribel ; Nair, Nikitha ; Minelli, Rosalba ; Chong, Zechen ; Chen, Fengju ; Chang, Qing Edward ; Dennison, Jennifer B. ; Dogruluk, Armel ; Li, Min ; Ying, Haoqiang ; Bertino, Joseph R. ; Gingras, Marie Claude ; Ittmann, Michael ; Kerrigan, John ; Chen, Ken ; Creighton, Chad J. ; Eterovic, Karina ; Mills, Gordon ; Scott, Kenneth L. / Functional annotation of rare gene aberration drivers of pancreatic cancer. In: Nature Communications. 2016 ; Vol. 7.
@article{0bce55ea03494570a9d69704138622fe,
title = "Functional annotation of rare gene aberration drivers of pancreatic cancer",
abstract = "As we enter the era of precision medicine, characterization of cancer genomes will directly influence therapeutic decisions in the clinic. Here we describe a platform enabling functionalization of rare gene mutations through their high-throughput construction, molecular barcoding and delivery to cancer models for in vivo tumour driver screens. We apply these technologies to identify oncogenic drivers of pancreatic ductal adenocarcinoma (PDAC). This approach reveals oncogenic activity for rare gene aberrations in genes including NAD Kinase (NADK), which regulates NADP(H) homeostasis and cellular redox state. We further validate mutant NADK, whose expression provides gain-of-function enzymatic activity leading to a reduction in cellular reactive oxygen species and tumorigenesis, and show that depletion of wild-type NADK in PDAC cell lines attenuates cancer cell growth in vitro and in vivo. These data indicate that annotating rare aberrations can reveal important cancer signalling pathways representing additional therapeutic targets.",
author = "Tsang, {Yiu Huen} and Turgut Dogruluk and Tedeschi, {Philip M.} and Joanna Wardwell-Ozgo and Hengyu Lu and Maribel Espitia and Nikitha Nair and Rosalba Minelli and Zechen Chong and Fengju Chen and Chang, {Qing Edward} and Dennison, {Jennifer B.} and Armel Dogruluk and Min Li and Haoqiang Ying and Bertino, {Joseph R.} and Gingras, {Marie Claude} and Michael Ittmann and John Kerrigan and Ken Chen and Creighton, {Chad J.} and Karina Eterovic and Gordon Mills and Scott, {Kenneth L.}",
year = "2016",
month = "1",
day = "25",
doi = "10.1038/ncomms10500",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Functional annotation of rare gene aberration drivers of pancreatic cancer

AU - Tsang, Yiu Huen

AU - Dogruluk, Turgut

AU - Tedeschi, Philip M.

AU - Wardwell-Ozgo, Joanna

AU - Lu, Hengyu

AU - Espitia, Maribel

AU - Nair, Nikitha

AU - Minelli, Rosalba

AU - Chong, Zechen

AU - Chen, Fengju

AU - Chang, Qing Edward

AU - Dennison, Jennifer B.

AU - Dogruluk, Armel

AU - Li, Min

AU - Ying, Haoqiang

AU - Bertino, Joseph R.

AU - Gingras, Marie Claude

AU - Ittmann, Michael

AU - Kerrigan, John

AU - Chen, Ken

AU - Creighton, Chad J.

AU - Eterovic, Karina

AU - Mills, Gordon

AU - Scott, Kenneth L.

PY - 2016/1/25

Y1 - 2016/1/25

N2 - As we enter the era of precision medicine, characterization of cancer genomes will directly influence therapeutic decisions in the clinic. Here we describe a platform enabling functionalization of rare gene mutations through their high-throughput construction, molecular barcoding and delivery to cancer models for in vivo tumour driver screens. We apply these technologies to identify oncogenic drivers of pancreatic ductal adenocarcinoma (PDAC). This approach reveals oncogenic activity for rare gene aberrations in genes including NAD Kinase (NADK), which regulates NADP(H) homeostasis and cellular redox state. We further validate mutant NADK, whose expression provides gain-of-function enzymatic activity leading to a reduction in cellular reactive oxygen species and tumorigenesis, and show that depletion of wild-type NADK in PDAC cell lines attenuates cancer cell growth in vitro and in vivo. These data indicate that annotating rare aberrations can reveal important cancer signalling pathways representing additional therapeutic targets.

AB - As we enter the era of precision medicine, characterization of cancer genomes will directly influence therapeutic decisions in the clinic. Here we describe a platform enabling functionalization of rare gene mutations through their high-throughput construction, molecular barcoding and delivery to cancer models for in vivo tumour driver screens. We apply these technologies to identify oncogenic drivers of pancreatic ductal adenocarcinoma (PDAC). This approach reveals oncogenic activity for rare gene aberrations in genes including NAD Kinase (NADK), which regulates NADP(H) homeostasis and cellular redox state. We further validate mutant NADK, whose expression provides gain-of-function enzymatic activity leading to a reduction in cellular reactive oxygen species and tumorigenesis, and show that depletion of wild-type NADK in PDAC cell lines attenuates cancer cell growth in vitro and in vivo. These data indicate that annotating rare aberrations can reveal important cancer signalling pathways representing additional therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=84955444058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955444058&partnerID=8YFLogxK

U2 - 10.1038/ncomms10500

DO - 10.1038/ncomms10500

M3 - Article

C2 - 26806015

AN - SCOPUS:84955444058

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10500

ER -